Sun Yat-sen University: Lymphoma, Large B-Cell, Diffuse trials

The registry lists 19 Lymphoma, Large B-Cell, Diffuse studies with Sun Yat-sen University as lead sponsor. 12 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 15Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07601607Phase 1/2
• Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCLRecruitingNCT07494565Phase 2
• Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II StudyNot yet recruitingNCT07398638Phase 1/2
• Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B LymphomaRecruitingNCT07084662Phase 2/3
• Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruitingNCT07077512Phase 2
• Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLRecruitingNCT06760039Phase 1/2
• Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBLRecruitingNCT06742502Phase 2
• Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）RecruitingNCT06647940Phase 2
• A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma PatientsRecruitingNCT06569485Phase 2
• Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)RecruitingNCT06517511Phase 2
• Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL PatientsRecruitingNCT05577364Phase 1/2
• Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaNot yet recruitingNCT05381506Phase 2
• A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP TherapyStatus unknownNCT05527912Phase 2
• DLBCL Treatment in Children and AdolescentsCompletedNCT04726995
• A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab EraStatus unknownNCT04624971
• Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell LymphomaStatus unknownNCT04423549
• Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCLCompletedNCT04022005Phase 2
• GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCLStatus unknownNCT04021992Phase 2
• A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma PatientsStatus unknownNCT01793844